ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES VALUE ASSESSMENT OF TRANSFORMATIVE MEDICINES IN RARE DISEASES

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) offered a thought-provoking issue panel, Valuing Transformative Medicines in Rare Diseases: Methods and Madness, at the Society’s 19th Annual European Congress in Vienna, Austria. Paul Hodgkins, PhD, Vice President, Vertex Pharmaceuticals, Boston, MA, USA moderated the session. Panelists included:
  • Ron Akehurst, DSc, Strategic Director, BresMed Health Solutions, Sheffield, UK
  • Alastair Kent, OBE, Director, Genetic Alliance UK, London, UK
  • Maarten Postma, PhD, Professor Pharmacoeconomics, Pharmacy Department, University of Groningen, Groningen, The Netherlands
Innovative treatments for rare diseases are often transformative for patients. This is especially true if the therapy is the first to treat a disease’s underlying cause, said moderator Paul Hodgkins. It can, however, be difficult to demonstrate clinical benefit and cost effectiveness due to a number of research challenges such as small sample sizes in clinical trials and the lack of good outcome measures. The question was raised, “Why should rare and/or ultra-rare conditions be treated any differently in health technology assessment than more common conditions?” Panelists examined the pros and cons of adhering to current methods and evidence standards versus employing alternative methodological approaches and data sources in rare disease treatment evaluation. Alastair Kent, OBE discussed the importance of patient values and priorities when developing rare disease treatments and outcome measures. ISPOR offers a number of working groups and resources related to this topic, including: Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×